Navigation Links
Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
Date:12/1/2011

, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.


'/>"/>
SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting
2. Generex Provides Update on Spinout of Antigen Express
3. Generex Augments Cash Position With Sales of Non-Essential Assets
4. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
5. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
6. Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America
7. Generex Provides Clarification of Facts
8. Generex Announces Results of Annual Stockholders Meeting
9. Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes
10. Generex Oral-lyn™ Data to be Presented at Two International Scientific Symposia
11. Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... , April 21, 2015 Invetech ... development, custom automation, and contract manufacturing, and  NanoCellect ... flow cytometry and cell sorting technology for life ... a novel flow cytometry platform. Headquartered ... Biomedical has developed a microchip-based cell sorting technology. ...
(Date:4/21/2015)... , April 21, 2015  scPharmaceuticals, Inc., ... pharmaceutical products for subcutaneous delivery, announced today ... of its investigational proprietary drug product, Furosemide ... associated with congestive heart failure. ... developing a proprietary patch pump.  The patch ...
(Date:4/21/2015)... Cleveleys (UK) (PRWEB) April 21, 2015 ... technology and its clinical applications will be ... Participants include engineers, scientists, regulators and clinicians ... The meeting is sponsored by Invibio Biomaterial ... polymer-based biomaterials, a specialist in manufacturing and ...
(Date:4/20/2015)... and MENLO PARK, Calif. ... Inc. (OTCQX: DMPI) (DelMar and the Company), ... proven cancer therapies in new orphan drug indications, ... 106th Annual Meeting of the American Association for ... potential for its lead product candidate VAL-083 ...
Breaking Biology Technology:NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 2NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 3scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 2scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 32nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 22nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 2DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 5
... VIPs, New Platform to Reach Wide Investor Audience, ... and,microprocessor technologies for use in portable monitoring devices,announced today ... using WallStreet VIPs, new platform on April 29, 2008 ... April 10 "SPO Medical is a company,on the ...
... DIEGO, April 10 MedImmune today announced that,researchers ... programs at the Annual Meeting of the American ... to,excellence in oncology research., "Cancer research has ... MedImmune and we,are proud to share data from ...
... Science Foundation,(NSF) has awarded Loma Linda University a ... lead a consortium in developing an,innovative model for ... Taylor, Ph.D., Professor of Microbiology,and Molecular Genetics, and ... project with Rohit Shukla, CEO and founder of ...
Cached Biology Technology:SPO Medical to Conduct Live Investor Meeting on April 29, 2008 2SPO Medical to Conduct Live Investor Meeting on April 29, 2008 3MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research 2MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research 3Loma Linda University Partners With Larta Institute for Technology Marketing Program 2
(Date:4/13/2015)... , April 13, 2015 ... Research, "Global Biometrics Market Forecast & Opportunities, 2020", the ... CAGR of around 14% till 2020. The biometrics ... large scale implementation and review of biometric management ... of new products with greater efficiency, are resulting ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a leading ... services, and Morpho, a leading supplier of biometric ... produce the market,s most advanced biometrically-enabled time clock, ... NXG time clock is setting a bold, new ... data for the small and mid-size employer. When ...
(Date:4/2/2015)... Sweden , April 2, 2015 ... for Q1 2015 attributed to somewhat higher than 125 ... in the year-end report 2014 that revenues for Q1 ... that the company reported for Q4 2014. The operating ... to be negative. The complete interim report will as ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Revises Revenues for Q1 2015 2
... The age-old maxim "Eat breakfast like a king, lunch like ... be the best advice to follow to prevent metabolic syndrome, ... study. Metabolic syndrome is characterized by abdominal obesity, ... The study, published online March 30 in the International ...
... . . A new pulsed magnet ... Source shatters previous field strength limits for pulsed neutron ... to develop the new technique, which uses a 30-Tesla ... high magnetic fields. ,Neutron scattering analysis at these high ...
... One of the most common house ant species might have ... in a forest, but the ants have found ways to ... Buczkowski, a Purdue University research assistant professor of entomology, found ... as they move from forest to city and act somewhat ...
Cached Biology News:Bacon or bagels? Higher fat at breakfast may be healthier than you think, says UAB research 2Story tips from the US Department of Energy's Oak Ridge National Laboratory April 2010 2Common house ants form supercolonies, prosper in urban settings 2
... AP Conjugate Stabilizer is an aqueous ... protein and other non-toxic stabilizing chemicals ... pH 5.5 6.5. This ... methylisothiazolone and 0.02% bromonitrodioxane as a ...
MAb to Myoglobin Cardiac...
... binding is a problem in your ... immobilized NeutrAvidin products as superior alternatives ... a modified avidin derivative that combines ... biotin-binding protein with exceptionally low nonspecific ...
Request Info...
Biology Products: